| pubmed-article:8858630 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8858630 | lifeskim:mentions | umls-concept:C0021888 | lld:lifeskim |
| pubmed-article:8858630 | lifeskim:mentions | umls-concept:C0048038 | lld:lifeskim |
| pubmed-article:8858630 | lifeskim:mentions | umls-concept:C0395482 | lld:lifeskim |
| pubmed-article:8858630 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:8858630 | lifeskim:mentions | umls-concept:C0392247 | lld:lifeskim |
| pubmed-article:8858630 | lifeskim:mentions | umls-concept:C0702240 | lld:lifeskim |
| pubmed-article:8858630 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:8858630 | pubmed:dateCreated | 1996-12-30 | lld:pubmed |
| pubmed-article:8858630 | pubmed:abstractText | Topical apraclonidine hydrochloride 1% is effective for controlling the intraocular pressure (IOP) rise following argon laser trabeculoplasty (ALT). The 0.5% formulation has recently become available commercially. The objective of this study was to compare the efficacy of these two concentrations for controlling IOP after ALT. | lld:pubmed |
| pubmed-article:8858630 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8858630 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8858630 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8858630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8858630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8858630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8858630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8858630 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8858630 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8858630 | pubmed:issn | 1082-3069 | lld:pubmed |
| pubmed-article:8858630 | pubmed:author | pubmed-author:ShieldsM BMB | lld:pubmed |
| pubmed-article:8858630 | pubmed:author | pubmed-author:ThrelkeldA... | lld:pubmed |
| pubmed-article:8858630 | pubmed:author | pubmed-author:AllinghamR... | lld:pubmed |
| pubmed-article:8858630 | pubmed:author | pubmed-author:AssalianA AAA | lld:pubmed |
| pubmed-article:8858630 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8858630 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:8858630 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8858630 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8858630 | pubmed:pagination | 657-60 | lld:pubmed |
| pubmed-article:8858630 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:meshHeading | pubmed-meshheading:8858630-... | lld:pubmed |
| pubmed-article:8858630 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8858630 | pubmed:articleTitle | Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty. | lld:pubmed |
| pubmed-article:8858630 | pubmed:affiliation | Duke University Eye Center, Durham, NC 27710, USA. | lld:pubmed |
| pubmed-article:8858630 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8858630 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8858630 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8858630 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
